Christine Knuehl

This inventor holds 9 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignees: Aveo Pharmaceuticals, Inc., Xoma Technology Ltd., Xoma Technologies, Ltd.. Active years: 2010-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christine Knuehl. Retrieved from https://idiyas.com/inventor/christine-knuehl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 1)

% Patents Active = 77.8

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 8.5

ph-index = 4

Forward Citations = 47(Granted Patents)

Company Filing History:

9 out of 42

Aveo Pharmaceuticals, Inc.

Xoma Technologies, Ltd.

patent

where one patent can have more than one assignee

Years Active: 2010-2015

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9096664 - Nucleic acid encoding hepatocyte growth factor (HGF) binding proteins (2015-08-04),

2. 8580930 - Hepatocyte growth factor (HGF) binding proteins (2013-11-12),

3. 8575318 - Hepatocyte growth factor (HGF) binding proteins (2013-11-05),

4. 8273355 - Hepatocyte growth factor (HGF) binding proteins (2012-09-25),

5. 8268315 - [object Object] (2012-09-18),

6. 7943344 - Hepatocyte growth factor (HGF) binding proteins (2011-05-17),

7. 7935502 - Hepatocyte growth factor (HGF) binding proteins (2011-05-03),

8. 7659378 - Hepatocyte growth factor (HGF) binding antibody (2010-02-09),

9. 7649083 - Hepatocyte growth factor (HGF) binding antibody (2010-01-19),

Title: Christine Knuehl: Innovator in Biomedicine

Introduction

Christine Knuehl, a prominent inventor based in Natick, Massachusetts, has made significant contributions to the field of biomedicine. With 9 patents to her name, her work focuses on developing therapeutic agents that have the potential to address critical health challenges.

Latest Patents

Christine's latest patents include innovations related to nucleic acid encoding hepatocyte growth factor (HGF) binding proteins. These binding proteins are designed to bind and neutralize the activity of hepatocyte growth factor, particularly human HGF. This technology offers promising avenues for diagnostic and therapeutic applications, especially in treating specific HGF responsive disorders such as certain HGF responsive tumors.

Career Highlights

Throughout her career, Christine has been associated with notable companies, including Aveo Pharmaceuticals, Inc. and Xoma Technology Ltd. Her work has consistently focused on enhancing medical treatments through innovative biotechnologies, demonstrating a commitment to advancing healthcare solutions.

Collaborations

Christine has collaborated with esteemed colleagues, including William M Winston, Jr. and S Kirk Wright. These partnerships have enriched her research and amplified the impact of her inventions in the medical field.

Conclusion

With her impressive track record and ongoing innovations, Christine Knuehl continues to be a driving force in the development of new biomedical therapies. Her dedication to advancing science and improving patient outcomes reflects the essence of modern medical research and innovation.

Profile summary based on public USPTO records.